AVBP — ArriVent Biopharma Balance Sheet
0.000.00%
- $854.11m
- $553.85m
- 26
- 22
- 36
- 16
Annual balance sheet for ArriVent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 37.3 | 163 | 150 | 219 |
| Net Total Receivables | 0.25 | 0.5 | 0.761 | 0.5 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 43 | 183 | 160 | 227 |
| Net Property, Plant And Equipment | 0 | 0.139 | 0.291 | 0.154 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 43 | 183 | 163 | 275 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 1.82 | 8.36 | 11.6 | 17.3 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 1.82 | 8.37 | 11.8 | 17.3 |
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 41.2 | 174 | 151 | 258 |
| Total Liabilities & Shareholders' Equity | 43 | 183 | 163 | 275 |
| Total Common Shares Outstanding |